← All trials
NCT05726630
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 26, 2022
- Primary completion
- Aug 1, 2024
- Completion date
- Feb 1, 2025
- First posted
- Feb 14, 2023
- Last posted
- Feb 14, 2023
- Enrollment
- 152
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- BiocadLead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.